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Objectives: Platelet products have been proposed as adjuvant therapy for wound healing. We undertook this study to
determine the healing effect of topically applied frozen autologous platelets (FAP) on chronic venous ulcers, compared
with effect of placebo, and whether use of topical FAP modifies local expression of vascular endothelial growth factor
(VEGF), keratinocyte growth factor (KGF), interleukin 8 (IL-8), and tissue inhibitor of metalloproteinase-1 (TIMP-1)
in wound fluid.
Methods: This randomized, placebo-controlled, double-blind trial was carried out in institutional practice, with ambula-
tory patients with proved chronic venous leg ulcers. In all patients, whole venous blood was drawn for preparation of
FAP. FAP or normal saline solution was applied three times per week for up to 12 weeks, together with hydrocolloids and
standardized compression bandages. Leg ulcer surface was assessed with numerical pictures. IL-8, VEGF, KGF, and
TIMP-1 levels were determined (enzyme-linked immunosorbent assay) in wound fluid after each 4 weeks of treatment.
Results: Fifteen patients were randomized into two groups with comparable leg ulcer characteristics. Mean percent
reduction in ulcer area was 26.2% in the FAP group versus 15.2% in the placebo group (P .94). One ulcer in each group
was completely healed at study end. Levels of TIMP-1 increased significantly during FAP treatment. IL-8 concentration
was significantly lower in wound fluid of healing ulcers than in the fluid of nonhealing ulcers, in both FAP and placebo
groups. Growth factor levels were not modified with FAP treatment.
Conclusion: Topical autologous platelets have no significant adjuvant effect on healing of chronic venous leg ulcers and
increased wound fluid TIMP-1 concentration. Ulcer healing is associated with a decrease in wound fluid IL-8. (J Vasc
Surg 2003;38:1342-8.)
Venous ulcers are chronic wounds associated with
long-standing venous hypertension. The main goals of
venous ulcer treatment are to counteract or eliminate trans-
mission of increased venous pressure to the skin and to
improve local wound care. Despite recent improvements in
dressings, no drug or local adjuvant wound treatment is
widely accepted as standard therapy because the reasons for
nonhealing of chronic venous ulcers are poorly under-
stood.1 The prognosis for healing of large, long-standing
venous ulcers is poor, and these ulcers could particularly
benefit from alternative therapies to speed the healing
process.2 Cutaneous wound repair is the result of a complex
set of interactions among inflammatory and resident cells,
soluble mediators, and extracellular matrix.3 Blood plate-
lets have a major role in initiation of cutaneous wound
healing. They adhere, aggregate, and release numerous
growth factors, adhesive molecules, and lipids that regulate
the migration, proliferation, and functions of keratinocytes,
fibroblasts, and endothelial cells.4-8 It was demonstrated in
a porcine model of a cutaneous wound that platelets and
fibroblasts are the main inducers of granulation tissue for-
mation.9 Implication of growth factors in tissue repair has
led to abundant animal and clinical research on local appli-
cation of platelet products or recombinant growth factor as
adjuvant therapy for healing of a variety of wound tissues,
such as skin, bone, and nervous tissue.10-12 Supernatants of
thrombin-activated platelets—that is, platelet-derived
wound healing factors—have been widely used since 1990
in wound care centers in the United States as topical
adjuvant therapy for cutaneous wound healing.13
To our knowledge, local production of mediators such
as growth factor, cytokines, and metalloproteinases and
their inhibitors in wounds treated with platelet products
has not been reported. Therefore we analyzed the thera-
peutic effect of a platelet product and its local biological
effect on chronic venous ulcers. The primary purpose of the
study was to determine, in a randomized, double-blind,
placebo-controlled trial, the healing effect of topically ap-
plied frozen autologous platelets (FAP) on chronic venous
ulcers. Our secondary goal was to determine the level of
growth factor (keratinocyte growth factor [KGF], vascular
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endothelial growth factor [VEGF]) of an inflammatory
cytokine (interleukin 8 [IL-8]) and of a tissue inhibitor of
metalloproteinase-1 (TIMP-1) in wound fluid from
chronic venous ulcers treated with FAP or placebo.
METHODS
Study design. The study was conducted at Saint-
Louis Hospital (Paris, France) between January 1998 and
December 2000, in accordance with the Declaration of
Helsinki. Informed written consent was obtained from
each patient before entry to the study. The protocol was
approved by the local ethics committee. The study was a
one-center, randomized, double-blind, placebo-con-
trolled, parallel group clinical trial. Its purpose was to
compare the effect of topically applied FAP suspension in
saline solution versus placebo (normal saline solution) for
up to 12 weeks on healing of venous leg ulcers (rate and
time to complete healing) in patients who were already
receiving standard topical treatment and compression
therapy.
Patients. Patients with one or more venous leg ulcers
were enrolled in the study and assessed with the CEAP
classification.14 Patients who complied with entry and ex-
clusion criteria were randomized to one of two treatment
groups. All patients received standardized conservative
treatment of leg ulcers. Concomitant medications for other
illnesses were continued.
Inclusion criteria included age 18 years or older; pres-
ence of at least one venous ulcer; ulcer duration at least 2
months; reference ulcer surface 3 to 50 cm2; no tendency
for healing in the past 2 months; clinical findings consistent
with established venous disease (skin hyperpigmentation,
varicose veins, lipodermatosclerosis) and confirmed at ve-
nous duplex ultrasound (US) scanning during the preced-
ing 6 months; absence of significant arterial insufficiency
assessed at clinical examination (intermittent claudication
or resting pain, necrotic or distal wound on the foot) and by
the presence of either systolic homolateral ankle-brachial
index greater than 0.8 or peripheral pulses; ability to give
informed consent and to follow the treatment procedure;
and platelet count greater than 150,000/mm3, hemoglo-
bin greater than 11 g/dL, and albumin concentration
greater than 35 g/L. Exclusion criteria included preg-
nancy; allergy to hydrocolloid dressings; uncontrolled or
evolving systemic disease (cardiac or renal failure, hepatic
insufficiency, malignant disease, diabetes mellitus, rheuma-
toid arthritis, other connective tissue disorder); serum cre-
atinine concentration greater than 180 mol/L; systemic
treatment with corticosteroid agents or cytotoxic drugs;
limited physical capacity or total immobility; ulcers with
exposed tendons or bones; infected ulcer requiring sys-
temic antibiotic treatment; history of poor compliance with
compression therapy; positive viral serologic finding of
human immunodeficiency virus, hepatitis C, or human T
lymphocyte virus I or II; presence of antibodies against
hepatitis B surface antigen or hepatitis B core antigen;
serologic test results positive for syphilis; or abnormal re-
sults of liver function test. Patients with diabetes could be
included if glucose concentration was less than 2 g/L with
appropriate treatment.
Collection and preparation of FAP. Whole venous
blood was drawn at the hospital blood bank at a maximal
volume of 7 mL/kg into a sterile bag (Baxter SA, La
Chaˆtre, France) containing citrate-phosphate-dextrose af-
ter standard blood donation procedures. After 2 hours of
storage at room temperature (22°C  2°C), first-step
centrifugation at 5000g for 7 minutes was performed, to
separate platelet-containing buffy coat from red blood cells.
Red blood cells were transfused the same day into the
patient. The buffy coat was stored overnight at room
temperature (22°C 2°C), then centrifuged at 300g for 5
minutes to separate platelet-rich plasma from white blood
cells and residual red blood cells, which were discarded.
Platelet-rich plasma was transferred into sterile tubes after
counting (Sysmex), then centrifuged at 1500g for 10 min-
utes at 20°C, and the platelet-poor plasma was decanted.
Platelets were gently resuspended in normal saline solution
at a final concentration of 5  108/mL, and the platelet
suspension was divided into 1 mL aliquots (minimum of 36
aliquots per patient) and cryopreserved at80°C. For each
patient, aliquots of 1 mL of normal saline solution (pla-
cebo) were also prepared (36 aliquots) and cryopreserved
before randomization.
Treatment procedure. At baseline, a general medical
history was obtained and physical examination performed.
When several ulcers were present, the largest ulcer was
designated the reference ulcer. The surface was estimated
on the first day by measurement of wound length and
width, to determine the appropriate volume of either FAP
or placebo to apply topically.15 Platelet dosage was 107
platelets/cm2 of initial wound surface. The volume of
applied placebo or platelets was maintained throughout the
study for each patient. Immediately after collection and
preparation of platelets, patients were randomized to re-
ceive either placebo or platelets. Thereafter patients at-
tended the Clinical Investigation Center for ulcer treat-
ment, three times a week, until either complete healing (full
epithelialization) or 12 weeks of treatment. Dressings were
changed three times per week, but only at the center, not at
home. After the wound was cleansed with normal saline
solution, the appropriate volume of either FAP or placebo
was applied to the wound surface with a syringe. FAP and
placebo appeared identical. Standardized dressing and
compression bandages were replaced after each application.
In both groups, dressings used were hydrocolloid (Comfeel
Plus Opaque; Coloplast, Fontenay-Sous-Bois, France). All
patients received standard graded compression, with cotton
bandages (Nylex; Laboratoires URGO, Chenove, France)
and elastic bandages (Biflex Plus Forte; Laboratoires Thua-
sne, Levallois-Perret, France). If the treatment was inter-
rupted more than once or a patient could not continue
treatment for any reason, related or not to the study, that
patient was withdrawn and data were included in the anal-
ysis as treatment failure.
Wound assessment. Ulcer evaluation was performed
at entry and at 4-week intervals until either 4 weeks after
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complete healing or 16 weeks after enrollment. Surface
evaluation was assessed by measuring wound width and
length and with four successive numerical pictures at each
visit. Pictures were obtained with a Kodak DC 120 camera
(1280  960 pixels, 16.7 million colors) and standardized
for light and distance from the wound. Focal distance was
set at 30 cm throughout the study. The optical axis always
formed a right angle with the wound plane. The dimen-
sions and form of a semirigid frame with colorimetric
(white and black) and metric scales were determined before
the study, and this standardized frame was used for all
patients. Once placed on the wound, it entirely framed the
picture when the camera was placed at 90 degrees and 30
cm from the ulcer. The camera was turned so that the
optical axis remained the same. Reflections were elimi-
nated, because light came from the left for the first two
pictures and from the right for the last two pictures. The
metric scale of the frame was used to resize the picture on
the computer. Reflections were eliminated by superimpo-
sition of the resized pictures on the computer. Wound
outlines were manually determined on the computer by
one of us (P.S.) on the resized and recorded pictures. Each
picture was subsequently computer-processed, and the final
wound area and perimeter were taken as the mean of the
measurements calculated from the four pictures. Inasmuch
as change in area is independently influenced by initial area
and perimeter, we estimated wound healing rate by calcu-
lating the linear healing of the wound edge16:
D A/P,
where D is linear healing, A is change in area, and P is
mean perimeter.
To test intraobserver reproducibility of this wound-
outlining method before the study, 23 chronic leg ulcers
were measured three times by the same clinician (P.S.) with
this method, at 1-month intervals. The three repeated
measurements were compared with analysis of variance, and
did not show any significant difference (data not shown).
Interobserver reproducibility of the method was not as-
sessed, because it has been always reported as excellent in
the literature.17
Wound fluid sample collection. Samples of wound
fluid were obtained at entry to the study and every 4 weeks
during treatment (12 weeks). Wound fluid was collected
with a standardized method, as described.18 In brief, after
cleansing the wound with sterile saline solution, the leg
ulcer was covered with polyurethane film (Opsite; Smith &
Nephew, LeMans, France). The patient rested in the study
center, and after 6 hours the fluid was aspirated with a
syringe from beneath the dressing. The fluid was trans-
ferred to collection tubes and centrifuged at 2000g for 10
minutes to remove any debris. Supernatant was separated in
aliquots and stored immediately at 80°C until assay.
Growth factors and TIMP-1 assay in wound fluid
and platelet products. Commercial quantitative sand-
wich enzyme-linked immunoassay techniques were used to
determine concentrations of IL-8, VEGF, KGF, and
TIMP-1 in wound fluid, and platelet-derived growth factor
(PDGF)–AB, and transforming growth factor beta1
(TGF1) levels in platelet products. The IL-8 assay system
was obtained from Immunotech (Marseille, France), and
used two monoclonal antibodies. Other assay systems were
obtained from R&D Systems (Minneapolis, Minn), and
used a monoclonal capture antibody and a second poly-
clonal antibody for quantification. Assay reagents and
working standards were provided with the kits, and were
prepared according to the manufacturer’s instructions.
Samples and standards were diluted with the diluents ap-
propriate for serum sample dilution provided with the kits.
Standard curves were established with serial dilutions of the
corresponding recombinant protein. All samples were ana-
lyzed in duplicate. Interassay and intra-assay coefficients of
variation were all less than 10%. Sensitivity of each assay was
8 pg/mL for IL-8, 5 pg/mL for VEGF, 15 pg/mL for
KGF, 1.25 ng/mL for TIMP-1, 8.4 pg/mL for PDGF,
and 7 pg/mL for TGF1. The VEGF assay recognizes the
different isoforms of VEGF-A. Each cytokine level in
wound fluid was related to the corresponding total protein
concentration (Roche Diagnostic, Meylan, France). PDGF
and total TGF1 levels in FAP were determined after five
cycles of freezing and thawing to disrupt platelet mem-
branes. Results are expressed for 107 platelets.
Statistical analysis. The data were analyzed on an
intent-to-treat basis, and represent mean and standard de-
viation (SD), except where indicated. The Fisher exact test
was used to compare categorical data between groups. The
Mann-Whitney U test for unpaired populations was used to
compare numerical data between groups. The Mann-Whit-
ney U test for paired populations was used to compare
numeric data on two different days in the same group. All
tests were two-sided, and P  .05 was considered signifi-
cant. Analysis of variance was used to analyze ulcer size and
biological parameter evolution in each treatment group.
Statistical analysis was performed with Statview software
(ABACUS Concepts; Berkeley, Calif).
RESULTS
Epidemiologic data. Fifteen patients were randomly
assigned, eight in the FAP group and seven in the placebo
group. Patients were categorized according to the CEAP
system (Table I). The groups were comparable after ran-
domization. Two patients (one in each group) were with-
drawn from the final clinical analysis; one discontinued
participation in the study because of personal reasons, and
the other did not have a photographic assessment that
could be evaluated. Data for these two patients were in-
cluded in the analysis as failure to heal. Characteristics of
the two groups are summarized in Table I. No significant
difference was found between groups for ulcer size and
duration, type of venous insufficiency, or other character-
istics. Overall mean ulcer diameter in enrolled patients was
12.4  7.9 cm2.
Characterization of FAP. Concentration of
PDGF-AB and TGF1 in frozen autologous platelet sus-
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pensions was measured in prepared samples from 14 of 15
patients. PDGF-AB concentration was 0.50  0.18 ng/
107 platelets, and TGF1 concentration was 1.40  0.46
ng/107 platelets.
Clinical safety and efficacy of FAP on wound heal-
ing. FAP had no significant influence on venous ulcer
healing (Fig). There was no statistically significant differ-
ence in mean baseline ulcer diameter between the FAP and
placebo groups (respectively, 13.7  7.9 cm2 and 10.9 
8.4 cm2; P  .9). One ulcer in the FAP group and one in
the placebo group healed completely by study end (P 	
.05), after 12 and 4 weeks of treatment, respectively. No
relapse occurred during the 4 weeks after the end of the
treatment. Mean linear healing rate per day during the
study was .0033  .0061 cm/d in the FAP group and
.0021  .0058 in the placebo group (P  .47). Linear
healing of wound edge was not statistically different be-
tween the two groups at any time during the study. Mean
percent reduction in ulcer area was 26.2% in the FAP group
versus 15.2% in the placebo group (P  .94). Decrease in
ulcer area tended to be greater in the FAP group than in the
placebo group, but this difference did not reach signifi-
cance. No statistically significant difference was detected
between the two groups with respect to incidence of ad-
verse events. Adverse events included one wound infection
in the FAP group, which required treatment with oral
synergistin for 10 days, compared with no wound infection
in the placebo group; thrombophlebitis during blood sam-
pling in one patient in the FAP group, compared with none
in the placebo group; and irritative dermatitis around the
wound in two patients in each group. There was no
evidence of adverse effect specifically related to use of
FAP.
Induction of local production of growth factors in
leg ulcers treated with FAP. Growth factor and TIMP-1
levels were assessed to determine whether platelet treat-
ment influenced local secretion of these mediators. In a few
cases wound fluid volume was not sufficient to perform all
of the assays. Levels of the various factors in wound fluid at
different times during the study are presented in Table II.
Concentrations of growth factors and TIMP-1 in wound
fluid did not differ significantly between platelet and pla-
cebo groups at inclusion (day 0) or during the study.
Concentrations of IL-8, KGF, and VEGF were not signif-
icantly modified during the study in either group. TIMP-1
levels in wound fluid increased significantly during the
study in the FAP treatment group (P  .04).
When considering ulcer outcome at the end of the
study, in either group, no significant difference was found
between healing (n 7) and nonhealing (n 8) ulcers for
VEGF, TIMP-1, or KGF levels. IL-8 levels in wound fluid
were not significantly different between healing and non-
healing ulcers at the beginning of the study, but at the end
of the study IL-8 level was significantly lower in the healing
group (29.8  10.4 ng/mg) compared with the nonheal-
ing group (69.7  35.7 ng/mg; P  .04).
Table I. Characteristics of treatment groups
Patient characteristics FAP Placebo P
Demographic data
Age (y) 72.3 [45–88] 72.3 [50–83] NS
Sex (F/M) 3/4 3/3 NS
Body mass index (cm/kg2) 29.1 [18–42.3] 29 [23.9–35.6] NS
Diabetes 1/7 1/6 NS
Reference ulcer
No. of episodes of complete healing 0.29 [0–1] 0.3 [0–1] NS
Duration of reference ulcer (mo) 50.6 [4–240] 70 [24–120] NS
Mean surface area at baseline 13.7 [4.8–27.25] 10.85 [3.7–26.5] NS
Venous disease
Deep venous insufficiency 4/7 4/6 NS
Superficial venous insufficiency 4/7 3/6 NS
Popliteal reflux 3/7 4/6 NS
Postthrombotic syndrome 3/7 2/6 NS
Homolateral venous stripping 2/7 4/6 NS
CEAP classification
Clinical C6 7/7 6/6
Etiology
Ep 4/7 1/6
Es 2/7 3/6
Ec 0/7 3/6
Anatomy
As 4/7 3/6
Ad 4/7 4/6
Pathophysiology
Pr 5/7 4/6
Pro 2/7 2/6
Values in parentheses are range.
FAP, Frozen autologous platelets; NS, not significant.
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DISCUSSION
This study evaluated in a randomized double-blind
manner the clinical and biological effects of autologous
platelets as adjuvant treatment for venous ulcers. Com-
pared with placebo, FAP resulted in modest improvement
in venous ulcer healing, as measured by the rate of wound
area reduction, but the difference was not significant. Dur-
ing FAP treatment, local secretion of VEGF and KGF was
not modified in chronic venous ulcer wound fluid, but
TIMP-1 concentrations increased significantly. Moreover,
IL-8 levels in wound fluid were significantly lower at the
end of the study in healing venous ulcers in both groups.
Large ulcer diameter (mean,	12 cm2) and long dura-
tion of ulceration (	50 months) are predictors of poor
healing and long time to healing.2 Indeed, only large and
long-standing ulcers that are slow to heal may benefit from
alternative therapies such as topically applied platelet prod-
ucts.2 The severity of inclusion criteria in our study could
account for the homogeneity of the enrolled patients and
also for their small number. The 12-week treatment period
Linear healing of wound edge (mean  SEM) calculated at each visit for platelet group (line with diamonds) and placebo
group (line with squares). D  A/P, where D is linear healing, A is change in area, and P is mean perimeter).
Table II. IL-8, VEGF, TIMP-1, and KGF concentrations in wound fluid
Day 0 Day 28 Day 56 Day 84
IL-8 (ng/mg)
FAP 97.2  60.1 (n  7) 67.1  33.0 (n  8) 74.9  91.4 (n  7) 52.3  26.8 (n  7)
Placebo 57.0  48.4 (n  6) 38.7  18.3 (n  5) 24.5  0.1 (n  2) 59.7  50.1 (n  4)
VEGF (pg/mg)
FAP 369  123 (n  7) 507  408 (n  8) 520  630 (n  8) 373  250 (n  7)
Placebo 379  95 (n  6) 351  221 (n  5) 256  20 (n  2) 579  365 (n  4)
TIMP-1 (ng/mg)
FAP 7.4  2.9 (n  7) 14.2  7.3 (n  8) 13.7  6.3 (n  7) 15.1  7.9 (n  7)
Placebo 13.9  7.2 (n  6) 20.5  11.9 (n  5) 20.0  0.8 (n  2) 18.1  4.6 (n  3)
KGF (pg/mg)
FAP 41  37 (n  6) 43  18 (n  5) 81  55 (n  7) 69  26 (n  4)
Placebo 57  53 (n  3) 46  32 (n  4) 61  18 (n  2) 78  38 (n  2)
Values per milligram of total protein content.
IL-8, Interleukin-8; VEGF, vascular endothelial growth factor; TIMP-1 tissue inhibitor of metalloproteinase-1; KGF, keratinocyte growth factor.
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could be too short to observe substantial benefit in patients
with venous ulcers with poor prognosis. However, recently,
in a randomized trial versus placebo conducted in 86
patients with chronic venous ulcers, a platelet product had
no adjuvant effect, even when the treatment was continued
for 9 months.19
Various types of platelet products have been used for
tissue repair adjuvant therapy. Platelet releasates (platelet-
derived wound healing factors) are supernatants of autolo-
gous platelets that have been activated in vitro with throm-
bin.20 Platelet lysates are autologous platelets disrupted by
sonication and centrifuged to remove platelet fragments
from the solution.19 Our group has used autologous sus-
pensions of functional platelets for treatment of macular
holes.11 In the present study, we prepared platelet suspen-
sions according to the method described for treatment of
macular holes.11,21 For use during 12-week treatment of
chronic venous ulcers, platelet suspensions were prepared,
aliquoted, and frozen. Platelet suspensions prepared for
macular hole treatment were adherent, aggregated, and
mitogenic for glial cells (maximum, approximately 3 10 7
platelets/mL), and contained significant amounts of
PDGF, epithelial growth factor (EGF), and TGF1.
11,22 In
the present study, the same type of platelet suspension was
frozen until use, and therefore the platelets applied to the
wounds were no longer functional. We observed in vitro a
dose-dependent stimulatory effect of FAP on IL-8, VEGF,
KGF, and TIMP-1 production by adult dermal fibroblasts,
with a maximal effect at 108 platelets/mL (P. Senet, 1999).
The methods of blood collection (drawing of venous blood
or apheresis) and platelet preparation (with or without
activation with thrombin) modify the final platelet product
composition.23 Mean content of growth factor in FAP was
50 ng/109 platelets for PDGF and 140 ng/109 platelets
for TGF1. The quantity of FAP applied was adjusted
according to wound area, and mean quantity of growth
factor applied on the ulcer three times a week was 7 ng for
PDGF and 19 ng for TGF1. Growth factor platelet con-
tent could account for the adjuvant effect of growth factor
for tissue repair. However, after activation, platelets also
release adhesive proteins, mainly thrombospondin-1, and
lipid mediators, which have a role in angiogenesis regula-
tion and wound healing.6,24 It is noteworthy that it is
impossible to reproduce the effect of functional platelets
observed on glial cells in culture with recombinant growth
factors.22 These findings concerning platelet products used
for wound healing adjuvant therapy justify conducting
trials in homogeneous groups of patients treated with stan-
dardized and well-characterized platelet products.23
For chronic cutaneous wounds, it has been suggested
in two recent retrospective studies and one randomized
trial that platelet releasates may improve the chance for
healing of diabetic foot ulcers and decrease the risk for
amputation.10,13,25 Platelet releasates have been tested also
in two small studies in patients with leg ulcers from differ-
ent causes, with contradictory results.20,26 In a randomized
controlled trial, platelet lysates failed to improve healing of
chronic venous ulceration.19 Similarly, results of clinical
trials of topical recombinant growth factor on venous leg
ulcers have been disappointing.1,3 Thus neither platelet
products nor recombinant growth factors appear to have
any clear adjuvant effect on chronic venous ulcer healing.
The biological and cellular mechanisms of impaired
healing in venous ulcers are not well known, because of lack
of an animal model for this disease process. Studies have
focused on analysis of wound fluid, and also on biopsied
tissues, but these specimens are difficult to obtain, for
practical and ethical reasons. Several concepts have recently
emerged from the molecular and cellular analysis of the
chronic wound environment. Chronic venous ulcers are
associated with a chronic inflammatory state that is not
present in acute surgical wounds. Chronic venous ulcers
exhibit a long-standing inflammatory cellular infiltrate in
tissues, and elevated levels of proinflammatory cytokines in
wound fluid.27,28 Higher levels of IL-1, IL-6, and tissue
necrosis factor-
, and similar levels of various growth fac-
tors have been reported in nonhealing ulcers compared
with healing ulcers.27-30 Of interest, in our study IL-8,
which is implicated in recruitment of inflammatory cells to
the wound site, was present in a significantly lower concen-
tration in wound fluid of healing compared with nonheal-
ing ulcers. Concentrations of VEGF and KGF did not differ
between healing and nonhealing ulcers, as reported for
PDGF, EGF, basic fibroblast growth factor (bFGF), and
TGF.27,29 Therefore the results of our study and of others
in the literature suggest that the cellular environment of
chronic venous ulcers becomes less inflammatory as the
wound heals. In this study we also observed an increase in
wound fluid TIMP-1 concentrations during treatment with
FAP. The angiogenic effect of platelets is normally required
for induction of granulation tissue formation in acute
wounds.9 It was recently reported that fluid exudates from
long-standing venous ulcers inhibit experimental angio-
genesis.31 This inhibiting effect could be related to pres-
ence of antiangiogenic agents such as TIMP-1 in wound
fluid, which counteract the proangiogenic effect of growth
factors contained in topical platelet products.32
Fibroblasts isolated from venous ulcers are more senes-
cent compared with fibroblasts isolated from healthy skin,
and have decreased proliferative ability, dependent on ulcer
age.33-35 Indeed, chronic wound fibroblasts generally ex-
hibit a decreased mitogenic response to PDGF-AA, PDGF-
BB, bFGF, TGF1, and EGF, compared with normal or
acute wound fibroblasts.34,36 This may explain the poor
healing response to topical recombinant growth factors34
and to platelet products of long-standing venous ulcers, as
in our study. The absence of healing effect of the platelet
product on venous ulcers could also be due to destruction
of its components by wound proteases. High levels of
proteases are found in wound fluid from chronic venous
ulcers, impairing the healing process by degradation of
exogenous added growth factors such as EGF.18,37 This
raises the question of the possible delivery of platelet prod-
ucts together with protease inhibitors, by means of a poly-
meric device to control release of the growth factors and
prolong the biological effect of the various components.38
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In summary, we did not find any adjuvant therapeutic
effect of FAP for treatment of chronic venous ulcers. With
both FAP and placebo, ulcer healing was associated with a
decrease in local production of the inflammatory cytokine
IL-8. Thus it appears that local application of a platelet
product alone, in association with standard treatment, does
not improve healing of chronic venous ulcers.
We thank A. Chiali for assistance with blood collection
and randomization of patients.
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